CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations

Journal of Clinical Oncology

Volumn 22, Issue 4, 2004, Pages 624-633

  Fröhling, Stefan ^a   Schlenk, Richard F ^a   Stolze, Ina ^a   Bihlmayr, Jörg ^a   Benner, Axel ^a   Kreitmeier, Sylvia ^a   Tobis, Karen ^a   Döhner, Hartmut ^a   Döhner, Konstanze ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; FLT3 LIGAND; CCAAT ENHANCER BINDING PROTEIN; DDIT3 PROTEIN, HUMAN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; TRANSCRIPTION FACTOR; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; GENE MUTATION; GENE SEQUENCE; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; WILD TYPE; ACUTE DISEASE; DISEASE FREE SURVIVAL; FEMALE; GENETICS; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; MYELOID LEUKEMIA; PROSPECTIVE STUDY; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ADULT; CCAAT-ENHANCER-BINDING PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSCRIPTION FACTOR CHOP; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 1442356729     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.060     Document Type: Article

References (58)

1. Bloomfield CD, Lawrence D, Byrd JC, et al: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subgroup. Cancer Res 58:4173-4179, 1998
2. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
3. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
4. Mrózek K, Heinonen K, Bloomfield CD: Clinical importance of cytogenetics in acute myeloid leukaemia. Baillieres Best Pract Res Clin Haematol 14:19-47, 2001
5. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96:4075-4083, 2000
6. Döhner K, Tobis K, Ulrich R, et al: Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: A study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 20: 3254-3261, 2002
7. Fröhling S, Schlenk RF, Breitruck J, et al: Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100:4372-4380, 2002
8. Kottaridis PD, Gale RE, Frew ME, et al: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759, 2001
9. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002
10. van Waalwijk van Doorn-Khosrovani SB, Erpelinck C, van Putten WL, et al: High EVI1 expression predicts poor survival in acute myeloid leukemia: A study of 319 de novo AML patients. Blood 101:837-845, 2003
11. Whitman SP, Archer KJ, Feng L, et al: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study. Cancer Res 61:7233-7239, 2001
12. Tenen DG: Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3:89-101, 2003
13. Tenen DG, Hromas R, Licht JD, et al: Transcription factors, normal myeloid development, and leukemia. Blood 90:489-519, 1997
14. Ward AC, Loeb DM, Soede-Bobok AA, et al: Regulation of granulopoiesis by transcription factors and cytokine signals. Leukemia 14:973-990, 2000
15. Radomska HS, Huettner CS, Zhang P, et al: CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 18:4301-4314, 1998
16. Scott LM, Civin CI, Rorth P, et al: A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 80:1725-1735, 1992
17. Wang X, Scott E, Sawyers CL, et al: C/EBPα by-passes G-CSF signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood 94:560-571, 1999
18. Smith LT, Hohaus S, Gonzalez DA, et al: PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood 88:1234-1247, 1996
19. Hohaus S, Petrovick MS, Voso MT, et al: PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. Mol Cell Biol 15:5830-5845, 1995
20. Oelgeschlager M, Nuchprayoon I, Luscher B, et al: C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter. Mol Cell Biol 16:4717-4725, 1996
21. Ford AM, Bennett CA, Healy LE, et al: Regulation of the myeloperoxidase enhancer binding proteins Pu1, C-EBP alpha, -beta, and -delta during granulocyte-lineage specification. Proc Natl Acad Sci U S A 93:10838-10843, 1996
22. Khanna-Gupta A, Zibello T, Simkevich C, et al: Sp1 and C/EBP are necessary to activate the lactoferrin gene promoter during myeloid differentiation. Blood 95:3734-3741, 2000
23. Behre G, Singh SM, Liu H, et al: Ras signaling enhances the activity of C/EBP alpha to induce granulocytic differentiation by phosphorylation of serine 248. J Biol Chem 277:26293-26299, 2002
24. Friedman AD, McKnight SL: Identification of two polypeptide segments of CCAAT/enhancer-binding protein required for transcriptional activation of the serum albumin gene. Genes Dev 4:1416-1426, 1990
25. Lekstrom-Himes J, Xanthopoulos KG: Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem 273:28545-28548, 1998
26. Antonson P, Xanthopoulos KG: Molecular cloning, sequence, and expression patterns of the human gene encoding CCAAT/enhancer binding protein alpha (C/EBP alpha). Biochem Biophys Res Commun 215:106-113, 1995
27. Zhang DE, Zhang P, Wang ND, et al: Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A 94:569-574, 1997
28. Gombart AF, Hofmann WK, Kawano S, et al: Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 99:1332-1340, 2002
29. Pabst T, Mueller BU, Zhang P, et al: Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBP alpha), in acute myeloid leukemia. Nat Genet 27:263-270, 2001
30. Pabst T, Mueller BU, Harakawa N, et al: AML1-ETO downregulates the granulocytic differentiation factor C/EBP alpha in t(8;21) myeloid leukemia. Nat Med 7:444-451, 2001
31. Preudhomme C, Sagot C, Boissel N, et al: Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood 100:2717-2723, 2002
32. van Waalwijk van Doorn-Khosravani SB, Erpelinck C, Meijer J, et al: Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 4:31-40, 2003
33. Gilliland DG, Griffin JD: The roles of FLT3 in hematopoiesis and leukemia. Blood 100:1532-1542, 2002
34. Castilla LH, Garrett L, Adya N, et al: The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet 23:144-146, 1999
35. Okuda T, Cai Z, Yang S, et al: Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 91:3134-3143, 1998
36. Yergeau DA, Hetherington CJ, Wang Q, et al: Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 15:303-306, 1997
37. Yuan Y, Zhou L, Miyamoto T, et al: AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A 98:10398-10403, 2001
38. Beghini A, Peterlongo P, Ripamonti CB, et al: C-kit mutations in core binding factor leukemias. Blood 95:726-727, 2000
39. Gari M, Goodeve A, Wilson G, et al: C-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 105:894-900, 1999
40. Kiyoi H, Naoe T, Nakano Y, et al: Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074-3080, 1999
41. Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria of the classification of acute myeloid leukemia. Ann Intern Med 103: 620-625, 1985
42. Schlenk RF, Benner A, Hartmann F. et al: Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia 17:1521-1528, 2003
43. Mitelman F: ISCN (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, S. Karger, 1995
44. Fischer K, Scholl C, Sàlat J, et al: Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia. Blood 88:3962-3971, 1996
45. Fröhling S, Skelin S, Liebisch C, et al: Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol 20:2480-2485, 2002
46. Korn EL: Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5:255-260, 1986
47. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
48. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
49. Holm S: A simple sequentially rejective multiple test procedure. Scand J Stat 6:65-70, 1979
50. Cox DR: Regression models and life tables (with discussion). J R Stat Soc 34:187-220, 1972
51. Ihaka R, Gentleman R: R: A language for data analysis and graphics. J Comput Graph Stat 5:299-314, 1996
52. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
53. Vinson CR, Sigler PB, McKnight SL: Scissors-grip model for DNA recognition by a family of leucine zipper proteins. Science 246:911-916, 1989
54. Calkhoven CF, Muller C, Leutz A: Translational control of C/EBP alpha and C/EBP beta isoform expression. Genes Dev 14:1920-1932, 2000
55. Ossipow V, Descombes P, Schibler U: CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials. Proc Natl Acad Sci U S A 90:8219-8223, 1993
56. Lodie TA, Radomska HS, Donato LD, et al: PML/RARa induces ATRA-sensitive delocalization of the critical granulocytic differentiation factor C/EBP alpha to a microspeckled nuclear pattern in t(15;17) APL. Blood 94:692a, 1999 (abstr)
57. Truong BT, Lee YJ, Lodie TA, et al: CCAAT/enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. Blood 101:1141-1148, 2003
58. Iwasaki-Arai J, Zhang P, Huettner CS, et al: C/EBP alpha deficiency in hematopoiesis induces accumulation of non-malignant myeloblasts mimicking acute myelogenous leukemia. Blood 100:61a, 2002 (abstr)